Skip to content
OpenCapital
Get started

CNS Pharmaceuticals CNSP Q1 2026 Annual earnings

Reported May 14, 2026 · After market close

Diluted EPS-$7.30Miss by $1.93
EPS estimate-$5.37

Next report

Aug 17, 2026 (in a month)
EPS estimate-$0.24

Versus estimates

Diluted EPS

Q1 2026-$7.30Miss by $1.93
Q4 2025-$5.09In lineQ3 2025-$5.76Beat by $0.87Q2 2025-$6.42Beat by $3.18Q3 2024-$150.06Miss by $149.96Q2 2024-$4,033.61Miss by $448.18

Ask the moment CNS Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did CNS Pharmaceuticals report Q1 2026 earnings?
CNS Pharmaceuticals (CNSP) reported Q1 2026 earnings on May 14, 2026 after market close.
What were CNS Pharmaceuticals's Q1 2026 revenue and EPS?
CNS Pharmaceuticals reported diluted EPS of $-7.30 for Q1 2026.
Did CNS Pharmaceuticals beat estimates in Q1 2026?
EPS missed the consensus estimate of $-5.37 by $1.93.
Where can I find CNS Pharmaceuticals's Q1 2026 SEC filings?
You can read the 10-K periodic report (0001683168-26-002550) directly on SEC EDGAR. The filing index links above go to sec.gov.